Efficacy and safety of everolimus plus exemestane in patients with HR+, HER2− advanced breast cancer progressing on/after prior endocrine therapy in routine clinical practice: Primary results from the non-interventional study, STEPAUT

Efficacy and safety of everolimus plus exemestane in patients with HR+, HER2− advanced breast cancer progressing on/after prior endocrine therapy in routine clinical practice: Primary results from the non-interventional study, STEPAUT

Background: STEPAUT, an Austrian non-interventional study, evaluated the safety and efficacy of everolimus plus exemestane in patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2−) advanced breast cancer (ABC) recurring/progressing on/after nonsteroi...

Full description

Bibliographic Details
Main Authors: Guenther G. Steger, Daniel Egle, Rupert Bartsch, Georg Pfeiler, Edgar Petru, Richard Greil, Ruth Helfgott, Christian Marth, Leopold Öhler, Michael Hubalek, Alois Lang, Christoph Tinchon, Ferdinand Haslbauer, Andreas Redl, Karin Hock, Mathias Hennebelle, Bernhard Mraz, Michael Gnant
Format: Article
Language:English
Published: Elsevier 2020-04-01
Series:Breast
Subjects:
STEPAUT
Everolimus
Hormone receptor-positive
Metastatic breast cancer
Non-interventional study
Real-world setting
Online Access:http://www.sciencedirect.com/science/article/pii/S0960977620300369

Internet

http://www.sciencedirect.com/science/article/pii/S0960977620300369

Similar Items